Rapid reduction of substantially increased myoglobin and creatine kinase levels using a hemoadsorption device (CytoSorb®)—A case report
Authors:
Open Access
- 20 January 2022
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 10 (1) , e05272
Abstract
Rhabdomyolysis (RM) is a potentially life‐threatening entity that can lead to acute kidney injury (AKI). Continuous renal replacement therapy (CRRT) alone is known as effective therapy, but the additional use of a hemoadsorber (like CytoSorb®) might increase its efficacy.Keywords
This publication has 14 references indexed in Scilit:
- What Have We Learned about the Use of Cytosorb Adsorption Columns?Blood Purification, 2019
- 36th Vicenza Course on AKI & CRRTBlood Purification, 2018
- Extracorporeal membrane oxygenation and cytokine adsorptionJournal of Thoracic Disease, 2018
- Renal recovery after acute kidney injuryIntensive Care Medicine, 2017
- Delayed Nephrology Consultation and High Mortality on Acute Kidney Injury: A Meta-AnalysisBlood Purification, 2016
- Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practiceCritical Care, 2016
- Rhabdomyolysis: pathogenesis, diagnosis, and treatment.2015
- Continuous renal replacement therapy (CRRT) for rhabdomyolysisCochrane Database of Systematic Reviews, 2014
- Rhabdomyolysis: another complication after prolonged surgeryJournal of Clinical Anesthesia, 2007
- Rhabdomyolysis after laparoscopic donor nephrectomyUrology, 2002